The potential benefits of treating subclinical hypothyroidism include improvement in symptoms and quality of life, stopping progression to overt hypothyroidism and prevention of long- term complications. A previous systematic review of randomized controlled trials failed to demonstrate a benefit of levothyroxine treatment over placebo to improve symptoms or health- related quality of life in subclinical hypothyroidism. However, a subsequent randomized controlled trial found an improvement in tiredness with levothyroxine treatment. A recent randomized double- blind placebo- controlled trial of levothyroxine treatment in elderly patients (aged 65 years or above) failed to show an improvement in thyroid specific quality of life with the treatment in subclinical hypothyroidism. Furthermore, another randomized controlled trial in elderly patients (above the age of 65 years) found no benefit of levothyroxine in subclinical hypothyroidism to improve cognitive function.

There is some evidence to show improvement in lipid profile, features on echocardiography and cardiac magnetic resonance imaging, and arterial stiffness with levothyroxine replacement in subclinical hypothyroidism. However, at present, there are no large scale randomized controlled trials to show that levothyroxine treatment improves cardiovascular or cerebrovascular morbidity and mortality in subclinical hypothyroidism. Interestingly, a large observational study based on the UK general practice research database has found a reduction in fatal and non- fatal coronary heart disease events with levothyroxine in younger patients (aged between 40 and 70 years) with subclinical hypothyroidism, but not in older patients above the age of 70 years. In contrast, a large cohort study based on the Danish national registries showed no evidence of reduction in myocardial infarction, cardiovascular deaths, or all- cause mortality with levothyroxine treatment in patients with subclinical hypothyroidism, although all- cause mortality was reduced in patients under the age of 65 years.

اخر الاخبار

اخبار العتبة العباسية المقدسة

قسم التطوير يقدم دورة عن أخلاقيات المهنة ضمن برنامج تأهيل المنتسبين الجدد

ضمن برنامج (وفاءً للدماء).. المجمع العلمي يقيم محفلًا قرآنيًّا في محافظة المثنى

قسم الشؤون الفكرية يرفد المكتبة المركزية في ديالى بإصدارات معرفية

قسم التطوير يبحث مع ديوان الوقف الشيعي آفاق التعاون في مجال التدريب والتطوير المؤسسي

المزيد

الآخبار الصحية

خبير يكشف 5 حقائق طبية صادمة وغير معروفة

ليس الأسود ولا الحيتان.. "كائن صغير" هو أخطر قاتل للبشر!

بارقة أمل لمرضى "الإيدز".. علاج خلوي ينجح في كبح الفيروس

ظاهرة مقلقة تتوسع.. "المستنشقات" خطر صامت يهدد المراهقين

المزيد

الآخبار التكنلوجية

اكتشاف مادة في الثوم تحسن قوة العضلات وتبطئ شيخوختها

تطور الحياة على الأرض المبكرة اعتمد على معدن نادر

باحثون صينيون يطوّرون بطارية مائية قد تعمل 300 عام

الذكاء الاصطناعي..هل يصبح متهما جنائيا في الجرائم والانتحار؟

المزيد

مواضيع ذات صلة

Long- Term Complications of Subclinical Hypothyroidism

Myxoedema Coma: Thyroid Hormone Therapy

Myxoedema Coma: Hyponatraemia

Diagnosis of Myxoedema Coma

Pathophysiology of Unstable Hemoglobin Disorders

Central Hypothyroidism

Severe Iodine Deficiency and natural Goitrogens

Iatrogenic Hypothyroidism

Pathobiology of Sickle Cell Disease: The Basis of Phenotypic Diversity

The Unique Systems Biology of Sickle Cell Anemia

Abnormalities of Sickle Red Blood Cells

Abnormal Molecular Behaviors of Sickle Hemoglobin